IFNA1 and systemic lupus erythematosus: Anti-interferon α receptor monoclonal antibody anifrolumab targets the IFN-α receptor and has shown promise in SLE following TULIP I and II trials, impacting multiple type I and II IFN-induced gene modules/pathways and type III IFN-λ protein levels [243].